The biologic half-life of heparin
- PMID: 761447
- DOI: 10.1002/cpt1979253372
The biologic half-life of heparin
Abstract
Half-lives (t1/2s) varying from 23 min to 2.48 hr have been reported for heparin. It is shown that much of the discrepancy between authors can be attributed to methods used to analyze data. It is suggested that three terms should be carefully used, the t1/2 of bioassayed heparin concentration, the t1/2 of the extension of the clotting time, and the t 1/2 of the clotting time to differentiate among the various methods of analyzing the raw data.
Similar articles
-
The heterogeneity of the anticoagulant response to heparin.J Clin Pathol. 1972 Jan;25(1):45-8. doi: 10.1136/jcp.25.1.45. J Clin Pathol. 1972. PMID: 5015373 Free PMC article.
-
[Mechanism of action of heparin].Verh K Acad Geneeskd Belg. 1986;48(1):33-49. Verh K Acad Geneeskd Belg. 1986. PMID: 3739420 Dutch. No abstract available.
-
The fate of heparin in the body.Curr Ther Res Clin Exp. 1975 Jul;18(1 Pt1):45-57. Curr Ther Res Clin Exp. 1975. PMID: 808390 No abstract available.
-
[Heparin in therapeutics (author's transl)].Rev Med Brux. 1981 Mar;2(3):181-9. Rev Med Brux. 1981. PMID: 7015442 Review. French. No abstract available.
-
Molecular weight of heparin versus biologic activity. Some additional considerations.Semin Thromb Hemost. 1985 Jan;11(1):29-33. doi: 10.1055/s-2007-1004355. Semin Thromb Hemost. 1985. PMID: 2579437 Review. No abstract available.
Cited by
-
Clinical pharmacokinetics of heparin.Clin Pharmacokinet. 1980 May-Jun;5(3):204-20. doi: 10.2165/00003088-198005030-00002. Clin Pharmacokinet. 1980. PMID: 6993082 Review.
-
Heparin requirements for full anticoagulation are higher for patients on dabigatran than for those on warfarin - a model-based study.Clin Pharmacol. 2015 Feb 5;7:19-27. doi: 10.2147/CPAA.S72185. eCollection 2015. Clin Pharmacol. 2015. PMID: 25709508 Free PMC article.
-
Pharmacokinetic modeling of heparin and its clinical implications.J Pharmacokinet Biopharm. 1979 Aug;7(4):331-54. doi: 10.1007/BF01062533. J Pharmacokinet Biopharm. 1979. PMID: 512841
-
Enhanced vascularization in hybrid PCL/gelatin fibrous scaffolds with sustained release of VEGF.Biomed Res Int. 2015;2015:865076. doi: 10.1155/2015/865076. Epub 2015 Mar 25. Biomed Res Int. 2015. PMID: 25883978 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources